Stock analysis searches answered, part 21 of 43

Aifu inc. bullish and bearish analyst opinions

For “Aifu inc. bullish and bearish analyst opinions”, the matching SEC registrant is AIFU Inc., which trades as AIFU and files under Central Index Key 1413855. EDGAR puts it in the “Insurance Agents, Brokers & Service” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was AIX Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-21, across 423 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-28 by AIFU Inc. (CIK 1413855) — source document:

Our corporate origins trace to 1999 with the establishment of our initial operating entities in China, Guangzhou Nanyun Car Rental Services Co., Ltd. and Guangdong Nanfeng Automobile Association Co., Ltd. To facilitate offshore investment, we formed China United Financial Services Holdings Limited, or China United Financial Services, a British Virgin Islands company, as the offshore holding company of our PRC subsidiaries in 2001. In June 2004, CISG Holdings Ltd., or CISG Holdings was incorporated in British Virgin Islands and became our holding company through share exchanges with China United Financial Services. In anticipation of our initial public offering, we incorporated CNinsure Inc. in the Cayman Islands in April 2007. After a series of restructuring transactions, CNinsure Inc. became the ultimate holding company of our group.

Financial trend for AIFU Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 2,781,614,000 CNY (2022-12-31) to 556,567,000 CNY (2025-12-31), a change of -80.0%; net income (loss) went from 100,272,000 CNY (2022-12-31) to -2,275,386,000 CNY (2025-12-31), a change of -2369.2%; total assets went from 3,089,516,000 CNY (2022-12-31) to 1,528,098,000 CNY (2025-12-31), a change of -50.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1413855, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AIFU Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AIFU Inc. (CIK 1413855) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 226 8-K or 6-K reports in AIFU Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1413855 is on the EDGAR company page; the latest 20-F there is dated 2026-04-28 and the oldest filing in the recent index dates from 2007-10-10. Insider trades for AIFU Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Airjoule technologies corporation bullish and bearish analyst opinions

For “Airjoule technologies corporation bullish and bearish analyst opinions”, the matching SEC registrant is AirJoule Technologies Corp., which trades as AIRJ, AIRJW and files under Central Index Key 1855474. EDGAR puts it in the “Air-Cond & Warm Air Heatg Equip & Comm & Indl Refrig Equip” industry code with DE as its state or country of incorporation; its earlier registered name was Montana Technologies Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-16, across 306 filings on record. This is reference material, not trading advice.

Financial trend for AirJoule Technologies Corp. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $2.04 million (2022-12-31) to -$9.04 million (2025-12-31), a change of -542.7%; total assets went from $295.97 million (2022-12-31) to $340.64 million (2025-12-31), a change of +15.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1855474, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures AirJoule Technologies Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AirJoule Technologies Corp. (CIK 1855474) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 45 8-K or 6-K reports in AirJoule Technologies Corp.’s recent EDGAR index, the 4 listed here run from 2026-05-14 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1855474 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2021-07-12. Insider trades for AirJoule Technologies Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Akso health group bullish and bearish analyst opinions

For “Akso health group bullish and bearish analyst opinions”, the matching SEC registrant is Akso Health Group, which trades as AHG and files under Central Index Key 1702318. EDGAR puts it in the “Services-Business Services, NEC” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Xiaobai Maimai Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 20-F filed 2026-07-23, across 195 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-07-23 by Akso Health Group (CIK 1702318) — source document:

In April 2016, Hexindai Inc. was incorporated in Cayman Islands as a holding company. We provided online microlending business and P2P marketplace business from 2017 to 2019. As part of our major business restructuring and disposition of our P2P marketplace business in and around December 2020, which is described in greater detail below, we changed our name from Hexindai Inc. to Xiaobai Maimai Inc. to reflect our business that was built upon our social e-commerce platform. On December 3, 2021, we changed our name from Xiaobai Maimai Inc. to Akso Health Group in recognition of our focus on our new business development in the health sector. As of the date of this annual report, we are no longer engaged in the P2P marketplace businesses and are not making any new loans under the microlending business, and are no longer engaged in social e-commerce platform business, the Company currently focused on sale of medical devices business and provision of marketing promotion business.

Financial trend for Akso Health Group from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from $13.18 million (2023-03-31) to $13.83 million (2026-03-31), a change of +4.9%; net income (loss) went from -$1.36 million (2023-03-31) to -$18.67 million (2026-03-31), a change of -1273.0%; total assets went from $20.46 million (2023-03-31) to $189.63 million (2026-03-31), a change of +826.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1702318, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Akso Health Group did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Akso Health Group (CIK 1702318) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-07-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 96 8-K or 6-K reports in Akso Health Group’s recent EDGAR index, the 4 listed here run from 2025-05-01 to 2026-05-13, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1702318 is on the EDGAR company page; the latest 20-F there is dated 2026-07-23 and the oldest filing in the recent index dates from 2017-04-07. Insider trades for Akso Health Group appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alarum technologies ltd. bullish and bearish analyst opinions

For “Alarum technologies ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Alarum Technologies Ltd., which trades as ALAR and files under Central Index Key 1725332. EDGAR puts it in the “Services-Prepackaged Software” industry code with Israel as its state or country of incorporation; its earlier registered name was Safe-T Group Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-08-27, across 359 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-19 by Alarum Technologies Ltd. (CIK 1725332) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS. 41 A. Operating Results. 45 B. Liquidity and Capital Resources. 49 C. Research and Development, Patents and Licenses, etc. 51 D. Trend Information. 51 E. Critical Accounting Estimates. 51 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES. 52 A. Directors and Senior Management. 52 B. Compensation. 55 C. Board Practices. 56 D. Employees. 69 E. Share Ownership. 70 F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation. 72 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS. 72 A. Major Shareholders. 72 B. Related Party Transactions. 73 C. Interests of Experts and Counsel. 73 ITEM 8. FINANCIAL INFORMATION. 73 A. Consolidated Statements and Other Financial Information. 73 B. Significant Changes. 74 ITEM 9.

Financial trend for Alarum Technologies Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $18.55 million (2022-12-31) to $40.76 million (2025-12-31), a change of +119.7%; net income (loss) went from -$13.15 million (2022-12-31) to $963,000 (2025-12-31), a change of +107.3%; total assets went from $22.37 million (2022-12-31) to $45.89 million (2025-12-31), a change of +105.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1725332, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Alarum Technologies Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Alarum Technologies Ltd. (CIK 1725332) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 179 8-K or 6-K reports in Alarum Technologies Ltd.’s recent EDGAR index, the 4 listed here run from 2026-07-13 to 2026-08-27, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1725332 is on the EDGAR company page; the latest 20-F there is dated 2026-03-19 and the oldest filing in the recent index dates from 2018-01-08. Insider trades for Alarum Technologies Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alx oncology holdings inc. bullish and bearish analyst opinions

For “Alx oncology holdings inc. bullish and bearish analyst opinions”, the matching SEC registrant is ALX ONCOLOGY HOLDINGS INC, which trades as ALXO and files under Central Index Key 1810182. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13D/A filed 2026-10-16, across 421 filings on record. This is reference material, not trading advice.

Financial trend for ALX ONCOLOGY HOLDINGS INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2022-12-31 at $0; net income (loss) went from -$123.48 million (2022-12-31) to -$101.69 million (2025-12-31), a change of +17.6%; total assets went from $306.49 million (2022-12-31) to $59.05 million (2025-12-31), a change of -80.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1810182, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures ALX ONCOLOGY HOLDINGS INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ALX ONCOLOGY HOLDINGS INC (CIK 1810182) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 64 8-K or 6-K reports in ALX ONCOLOGY HOLDINGS INC’s recent EDGAR index, the 4 listed here run from 2026-06-26 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1810182 is on the EDGAR company page; the latest 10-K there is dated 2026-03-09 and the oldest filing in the recent index dates from 2020-05-05. Insider trades for ALX ONCOLOGY HOLDINGS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Alzamend neuro inc bullish and bearish analyst opinions

For “Alzamend neuro inc bullish and bearish analyst opinions”, the matching SEC registrant is Alzamend Neuro, Inc., which trades as ALZN and files under Central Index Key 1677077. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a RW filed 2026-10-09, across 397 filings on record. This is reference material, not trading advice.

Financial trend for Alzamend Neuro, Inc. from annual reports, periods 2023-04-30 to 2026-04-30: net income (loss) went from -$14.88 million (2023-04-30) to -$8.77 million (2026-04-30), a change of +41.0%; total assets went from $5.92 million (2023-04-30) to $2.08 million (2026-04-30), a change of -64.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1677077, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Alzamend Neuro, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Alzamend Neuro, Inc. (CIK 1677077) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2025-07-23, and the most recent 10-K annual report was filed 2026-07-22. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 69 8-K or 6-K reports in Alzamend Neuro, Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-17 to 2026-09-29, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 397 recent EDGAR filings, Alzamend Neuro, Inc. most often filed 4 (144), 8-K (69), CORRESP (19), 10-Q (16). A selection from 2026-08-31 to 2026-10-09:

The full record for CIK 1677077 is on the EDGAR company page; the latest 10-K there is dated 2026-07-22 and the oldest filing in the recent index dates from 2016-06-22. Insider trades for Alzamend Neuro, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ama marine public company limited bullish and bearish analyst opinions

Read from its name, “Ama marine public company limited” is a Thailand entity — “Public Company Limited” is the legal form Thai law requires for companies listed on SET or mai. Its accounts and exchange notices are published through the Stock Exchange of Thailand (SET) company pages and the SEC Thailand filing system (www.set.or.th); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Ama marine public company limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Ama marine public company limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “ama” (search terms considered: ama, marine, public).

Even the shorter phrase “Ama marine public” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (ama, marine, public) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 26 entities whose registered name contains the word “ama”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “ama” 26, “marine” 344, “public” 466. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “ama”: AMA DIRECT INVESTMENT PORTFOLIO LP (CIK 1036317), AMA EAGLE PRIVATE EQUITY FUND LP (CIK 1336197), AMA ENHANCED INDEX FUND QP LP (CIK 1209313); containing “marine”: ACE SECURITIES CORP RV & MARINE TRUST 2001-RV1 (CIK 1143991), AEGEAN EARTH & MARINE CORP (CIK 1368195), AEGEAN MARINE PETROLEUM NETWORK INC. (CIK 1344376); containing “public”: 30 THREE SIXTY PUBLIC FINANCE, INC. (CIK 1733578), 50T PUBLIC DAE FUND, LP (CIK 2099654), AAA PUBLIC ADJUSTING GROUP INC (CIK 1419697). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “ama” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Americasa home loans

What this search refers to. AmeriCasa home loans relates to a mortgage brand; mortgage lenders and brokers are licensed through the NMLS, whose Consumer Access site is the official check. EDGAR does list separate AmeriCasa-named private funds that filed Form D, which are investment vehicles, not the lender. Official source: www.nmlsconsumeraccess.org.

No SEC filer could be matched to “Americasa home loans” with a single, clear Central Index Key: the phrase “Americasa home loans” appears in 275+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “americasa” (search terms considered: americasa, home, loans).

In the 100 most relevant full-text hits returned for “Americasa home loans”, filings range from 2019-02-04 to 2025-08-07. The filers whose documents mention it most often are FEDERAL HOME LOAN MORTGAGE CORP (FMCC, FMCCG, FMCCI, FMCCJ, FMCCL, FMCCN, FMCCO, FMCCS, FMCCT, FMCKI, FMCKL, FMCKN, FREJN, FREJO) (CIK 0001026214) (57 hits); FEDERAL NATIONAL MORTGAGE ASSOCIATION FANNIE MAE (FNMA, FNMAG, FNMAH, FNMAI, FNMAJ, FNMAK, FNMAL, FNMAM, FNMAN, FNMAO, FNMAS, FNMAT, FNMFM, FNMFN) (CIK 0000310522) (43 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 4 entities whose registered name contains the word “americasa”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “americasa” 4, “home” 488, “loans” 145. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: if “americasa” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Amesite inc. bullish and bearish analyst opinions

For “Amesite inc. bullish and bearish analyst opinions”, the matching SEC registrant is Amesite Inc., which trades as AMST and files under Central Index Key 1807166. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation; its earlier registered name was Amesite Operating Co. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a ARS filed 2026-10-14, across 361 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-09-23 by Amesite Inc. (CIK 1807166) — source document:

Amesite is a technology company focused on building and commercializing AI (artificial intelligence)-powered solutions for the enterprise and for professionals, with particular emphasis on the post-acute healthcare market. In fiscal 2026, we launched a census-based Enterprise tier with EMR (electronic medical records) compatibility, automated interdisciplinary team reporting, and configurable documentation; introduced the AI-native NurseMagic™ EMR capability; and secured our largest enterprise deployment to date, serving an approximately 2,700-patient census. We operate through two product lines: NurseMagic™ and LynkMagic™. NurseMagic™ solutions include a B2B (business-to-business) enterprise application and a B2C (business-to-consumer) solution for individual healthcare professionals. LynkMagic™ provides enterprise AI solutions for healthcare and related organizations. Our products support documentation, workflow, compliance, oversight, and are designed to improve operational quality and efficiency.

Financial trend for Amesite Inc. from annual reports, periods 2023-06-30 to 2026-06-30: revenue went from $845,009 (2023-06-30) to $364,777 (2026-06-30), a change of -56.8%; net income (loss) went from -$4.15 million (2023-06-30) to -$3.10 million (2026-06-30), a change of +25.5%; total assets went from $6.35 million (2023-06-30) to $3.03 million (2026-06-30), a change of -52.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1807166, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Amesite Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Amesite Inc. (CIK 1807166) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2025-05-16, and the most recent 10-K annual report was filed 2026-09-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 71 8-K or 6-K reports in Amesite Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-13 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1807166 is on the EDGAR company page; the latest 10-K there is dated 2026-09-23 and the oldest filing in the recent index dates from 2020-04-14. Insider trades for Amesite Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ampco-pittsburgh corp. bullish and bearish analyst opinions

For “Ampco-pittsburgh corp. bullish and bearish analyst opinions”, the matching SEC registrant is AMPCO PITTSBURGH CORP, which trades as AP and files under Central Index Key 6176. EDGAR puts it in the “Pumps & Pumping Equipment” industry code with PA as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-23, across 1004 filings on record. This is reference material, not trading advice.

Financial trend for AMPCO PITTSBURGH CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $390.19 million (2022-12-31) to $434.17 million (2025-12-31), a change of +11.3%; net income (loss) went from $3.42 million (2022-12-31) to -$66.07 million (2025-12-31), a change of -2034.0%; total assets went from $502.77 million (2022-12-31) to $495.36 million (2025-12-31), a change of -1.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 6176, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AMPCO PITTSBURGH CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AMPCO PITTSBURGH CORP (CIK 6176) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 155 8-K or 6-K reports in AMPCO PITTSBURGH CORP’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-09-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1004 recent EDGAR filings, AMPCO PITTSBURGH CORP most often filed 4 (519), 8-K (155), 10-Q (56), SC 13D/A (47). A selection from 2026-06-22 to 2026-08-28:

The full record for CIK 6176 is on the EDGAR company page; the latest 10-K there is dated 2026-03-16 and the oldest filing in the recent index dates from 2007-12-11. Insider trades for AMPCO PITTSBURGH CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Amrep corporation bullish and bearish analyst opinions

For “Amrep corporation bullish and bearish analyst opinions”, the matching SEC registrant is AMREP CORP., which trades as AXR and files under Central Index Key 6207. EDGAR puts it in the “Land Subdividers & Developers (No Cemeteries)” industry code with OK as its state or country of incorporation; its earlier registered name was AMREP CORP. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-8 filed 2026-10-01, across 855 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-07-24 by AMREP CORP. (CIK 6207) — source document:

AMREP Corporation was organized in 1961 as an Oklahoma corporation and, through its subsidiaries, is primarily engaged in two business segments: land development and homebuilding. The Company has no foreign sales or activities outside the United States. The Company conducts a substantial portion of its business in Rio Rancho, New Mexico (“Rio Rancho”) and certain adjoining areas of Sandoval County, New Mexico. Rio Rancho is the third largest city in New Mexico with a population of approximately 114,000. Land Development As of April 30, 2026, the Company owned approximately 16,200 acres in Sandoval County, New Mexico. The Company develops both residential lots and sites for commercial and industrial use as demand warrants.

Financial trend for AMREP CORP. from annual reports, periods 2023-04-30 to 2026-04-30: net income (loss) went from $21.79 million (2023-04-30) to $10.29 million (2026-04-30), a change of -52.8%; total assets went from $115.89 million (2023-04-30) to $144.78 million (2026-04-30), a change of +24.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 6207, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AMREP CORP. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AMREP CORP. (CIK 6207) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-11, and the most recent 10-K annual report was filed 2026-07-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 228 8-K or 6-K reports in AMREP CORP.’s recent EDGAR index, the 4 listed here run from 2026-03-12 to 2026-09-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 6207 is on the EDGAR company page; the latest 10-K there is dated 2026-07-24 and the oldest filing in the recent index dates from 1994-01-26. Insider trades for AMREP CORP. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Anika therapeutics, inc. bullish and bearish analyst opinions

For “Anika therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Anika Therapeutics, Inc., which trades as ANIK and files under Central Index Key 898437. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation; its earlier registered name was ANIKA THERAPEUTICS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-08-07, across 1004 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-03 by Anika Therapeutics, Inc. (CIK 898437) — source document:

Purpose and Mission Founded in 1992, Anika Therapeutics, Inc. (“Anika” or “Company”) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid (“HA”) technology to develop highly differentiated products. Driven by strong partnerships with physicians, Anika is dedicated to pioneering HA-based innovations that redefine orthopedic care. Our mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide. Anika ’ s Mission: “Together, we restore active living and redefine what’s possible with hyaluronic acid.” Anika ’ s Core Values: ● Trust and Respect: We build trust and show respect in every interaction. ● Quality: We are committed to quality as we work to improve people’s lives. ● Empowerment & Teamwork: We are empowered as a team to make decisions that drive impact. ● Focus: We focus on what matters most and are driven to be better every day.

Financial trend for Anika Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $113.83 million (2022-12-31) to $112.82 million (2025-12-31), a change of -0.9%; net income (loss) went from -$14.86 million (2022-12-31) to -$10.88 million (2025-12-31), a change of +26.8%; total assets went from $349.13 million (2022-12-31) to $190.27 million (2025-12-31), a change of -45.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 898437, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Anika Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Anika Therapeutics, Inc. (CIK 898437) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-29, and the most recent 10-K annual report was filed 2026-03-03. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

The full record for CIK 898437 is on the EDGAR company page; the latest 10-K there is dated 2026-03-03 and the oldest filing in the recent index dates from 2003-12-19. Insider trades for Anika Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Apnimed, inc. bullish and bearish analyst opinions

For “Apnimed, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Apnimed, Inc., which trades as APMD and files under Central Index Key 1745648. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-8 filed 2026-09-08, across 54 filings on record. This is reference material, not trading advice.

Financial trend for Apnimed, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $17.11 million (2025-06-30) to $12.08 million (2026-06-30), a change of -29.4%; net income (loss) went from -$69.47 million (2025-06-30) to $125.94 million (2026-06-30), a change of +281.3%; total assets was tagged only for 2026-06-30 at $195.46 million. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1745648, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Apnimed, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Apnimed, Inc. (CIK 1745648) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-08. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 2 8-K or 6-K reports in Apnimed, Inc.’s recent EDGAR index, the 2 listed here run from 2026-08-03 to 2026-09-08, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 54 recent EDGAR filings, Apnimed, Inc. most often filed 3 (11), 4 (10), D (9), D/A (6). A selection from 2026-08-05 to 2026-09-08:

The full record for CIK 1745648 is on the EDGAR company page and the oldest filing in the recent index dates from 2018-07-06. Insider trades for Apnimed, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Arbe robotics ltd. bullish and bearish analyst opinions

For “Arbe robotics ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Arbe Robotics Ltd., which trades as ARBE and files under Central Index Key 1861841. EDGAR puts it in the “Services-Computer Integrated Systems Design” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-13 (this view begins at filings dated on or before 2026-09-15), across 216 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-27 by Arbe Robotics Ltd. (CIK 1861841) (passage 2, continuing from the earlier excerpt) — source document:

Consequently, for so long as we continue to meet such qualification, we will be subject to the reporting requirements under the Exchange Act applicable to foreign private issuers. We are required to file our annual report for each year with the SEC by April 30 of the following year. In addition, we will furnish reports on Form 6-K to the SEC regarding certain information that is distributed or required to be distributed by us to our shareholders.

Financial trend for Arbe Robotics Ltd. from quarterly and annual reports (three-month periods), periods 2025-03-31 to 2025-12-31: revenue went from $40,000 (2025-03-31) to $458,000 (2025-12-31), a change of +1045.0%; net income (loss) went from -$13.82 million (2025-03-31) to -$10.16 million (2025-12-31), a change of +26.5%; total assets went from $85.04 million (2025-03-31) to $74.61 million (2025-12-31), a change of -12.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1861841, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Arbe Robotics Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Arbe Robotics Ltd. (CIK 1861841) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 76 8-K or 6-K reports in Arbe Robotics Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-09-08, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1861841 is on the EDGAR company page; the latest 20-F there is dated 2026-03-27 and the oldest filing in the recent index dates from 2021-06-21. One example from this record is the 6-K filed 2026-09-28 (document). Insider trades for Arbe Robotics Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Argo graphene solutions corp. bullish and bearish analyst opinions

For “Argo graphene solutions corp. bullish and bearish analyst opinions”, the matching SEC registrant is ARGO GRAPHENE SOLUTIONS CORP., which trades as ARLSF and files under Central Index Key 1852354. EDGAR puts it in the “no SIC description” industry code with British Columbia, Canada as its state or country of incorporation; its earlier registered name was ARGO LIVING SOILS CORP. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a D filed 2026-09-28, across 5 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on ARGO GRAPHENE SOLUTIONS CORP. (CIK 1852354) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

What kind of filer this is matters for “Argo graphene solutions corp. bullish and bearish analyst opinions”: ARGO GRAPHENE SOLUTIONS CORP.’s EDGAR record from 2021-03-24 to 2026-09-28 consists only of Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it; as a company organised in British Columbia, Canada, its own reports would be with the Canadian Securities Administrators’ SEDAR+ system (www.sedarplus.ca).

Other filings. Across its 5 recent EDGAR filings, ARGO GRAPHENE SOLUTIONS CORP. most often filed D (5). A selection from 2021-03-24 to 2026-09-28:

The full record for CIK 1852354 is on the EDGAR company page and the oldest filing in the recent index dates from 2021-03-24. Insider trades for ARGO GRAPHENE SOLUTIONS CORP. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Atea pharmaceuticals, inc. bullish and bearish analyst opinions

For “Atea pharmaceuticals, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Atea Pharmaceuticals, Inc., which trades as AVIR and files under Central Index Key 1593899. EDGAR puts it in the “Pharmaceutical Preparations” industry code with MA as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-06, across 313 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-05 by Atea Pharmaceuticals, Inc. (CIK 1593899) — source document:

We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the potential to improve the current standard of care (“SOC”) for the treatment of patients with hepatitis C virus (“HCV”) infection and AT-587 which we believe has the potential to be the first direct-acting antiviral (“DAA”) for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus (“HEV”) infection. HCV - Our Goal and our Program The objective of our HCV development program is to improve upon the current SOC by offering bemnifosbuvir and ruzasvir as a differentiated pan-genotypic protease inhibitor-free, short-duration regimen for patients infected with HCV, if successfully developed and approved.

Financial trend for Atea Pharmaceuticals, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$115.91 million (2022-12-31) to -$158.35 million (2025-12-31), a change of -36.6%; total assets went from $666.71 million (2022-12-31) to $315.22 million (2025-12-31), a change of -52.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1593899, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Atea Pharmaceuticals, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Atea Pharmaceuticals, Inc. (CIK 1593899) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-03-05. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 41 8-K or 6-K reports in Atea Pharmaceuticals, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-05 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1593899 is on the EDGAR company page; the latest 10-K there is dated 2026-03-05 and the oldest filing in the recent index dates from 2013-12-11. Insider trades for Atea Pharmaceuticals, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Ategrity specialty holdings llc bullish and bearish analyst opinions

For “Ategrity specialty holdings llc bullish and bearish analyst opinions”, the matching SEC registrant is Ategrity Specialty Insurance Co Holdings, which trades as ASIC and files under Central Index Key 2040491. EDGAR puts it in the “Fire, Marine & Casualty Insurance” industry code with DE as its state or country of incorporation; its earlier registered name was Ategrity Specialty Holdings LLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21, across 62 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-06 by Ategrity Specialty Insurance Co Holdings (CIK 2040491) — source document:

Who we are Ategrity Specialty Insurance Company Holdings is a specialty property and casualty insurance holding company dedicated exclusively to the excess and surplus (“E&S”) market for small to medium-sized businesses (“SMBs”) across the United States. Our underwriting operations are conducted through Ategrity Specialty Insurance Company, a Delaware-domiciled E&S insurer (“Ategrity Specialty”). We underwrite small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. The SMB segment of the E&S market is characterized by a high volume of smaller-premium policies, where distribution partners expect speed, clarity, and consistency in the underwriting process. Our operating model uses a technology-driven method to standardize, simplify, and where appropriate, automate these transactions, which we call productionized underwriting . This method incorporates micro-segmentation, centralized underwriting governance, and automated workflows to promote consistent, disciplined execution across a high-volume of E&S transactions.

Financial trend for Ategrity Specialty Insurance Co Holdings from annual reports, periods 2024-12-31 to 2025-12-31: revenue went from $343.83 million (2024-12-31) to $424.34 million (2025-12-31), a change of +23.4%; net income (loss) went from $47.09 million (2024-12-31) to $74.00 million (2025-12-31), a change of +57.2%; total assets went from $1.12 billion (2024-12-31) to $1.47 billion (2025-12-31), a change of +31.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2040491, tags Assets, NetIncomeLoss, Revenues; 2 periods shown, dashes mark figures Ategrity Specialty Insurance Co Holdings did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Ategrity Specialty Insurance Co Holdings (CIK 2040491) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-21, and the most recent 10-K annual report was filed 2026-03-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 13 8-K or 6-K reports in Ategrity Specialty Insurance Co Holdings’s recent EDGAR index, the 4 listed here run from 2026-07-10 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2040491 is on the EDGAR company page; the latest 10-K there is dated 2026-03-06 and the oldest filing in the recent index dates from 2024-11-20. Insider trades for Ategrity Specialty Insurance Co Holdings appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Atossa therapeutics, inc. bullish and bearish analyst opinions

For “Atossa therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is ATOSSA THERAPEUTICS, INC., which trades as ATOS and files under Central Index Key 1488039. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was ATOSSA GENETICS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-09, across 641 filings on record. This is reference material, not trading advice.

Financial trend for ATOSSA THERAPEUTICS, INC. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$26.96 million (2022-12-31) to -$34.77 million (2025-12-31), a change of -29.0%; total assets went from $123.53 million (2022-12-31) to $47.61 million (2025-12-31), a change of -61.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1488039, tags Assets, NetIncomeLoss, SalesRevenueNet; 4 periods shown, dashes mark figures ATOSSA THERAPEUTICS, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ATOSSA THERAPEUTICS, INC. (CIK 1488039) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-07, and the most recent 10-K annual report was filed 2026-03-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 173 8-K or 6-K reports in ATOSSA THERAPEUTICS, INC.’s recent EDGAR index, the 4 listed here run from 2026-08-07 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 641 recent EDGAR filings, ATOSSA THERAPEUTICS, INC. most often filed 8-K (173), 4 (138), 10-Q (42), CORRESP (39). A selection from 2026-05-14 to 2026-08-07:

The full record for CIK 1488039 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2010-03-30. Insider trades for ATOSSA THERAPEUTICS, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Auburn national bancorporation, inc. bullish and bearish analyst opinions

For “Auburn national bancorporation, inc. bullish and bearish analyst opinions”, the matching SEC registrant is AUBURN NATIONAL BANCORPORATION, INC, which trades as AUBN and files under Central Index Key 750574. EDGAR puts it in the “State Commercial Banks” industry code with DE as its state or country of incorporation; its earlier registered name was AUBURN NATIONAL BANCORPORATION INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-17 by AUBURN NATIONAL BANCORPORATION, INC (CIK 750574) — source document:

Auburn National Bancorporation, Inc. (the “Company”) is a bank holding company registered with the Board of Governors of the Federal Reserve System (the “Federal Reserve”) under the Bank Holding Company Act of 1956, as amended (the “BHC Act”). The Company was incorporated in Delaware in 1990, and in 1994 it succeeded its Alabama predecessor as the bank holding company controlling AuburnBank, an Alabama state member bank with its principal office in Auburn, Alabama (the “Bank”). The Company and its predecessor have controlled the Bank since 1984. As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than currently are permitted to the Bank under applicable laws and regulations.

Financial trend for AUBURN NATIONAL BANCORPORATION, INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $598,000 (2022-12-31) to $619,000 (2025-12-31), a change of +3.5%; net income (loss) went from $10.35 million (2022-12-31) to $7.25 million (2025-12-31), a change of -29.9%; total assets went from $1.02 billion (2022-12-31) to $1.02 billion (2025-12-31), a change of -0.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 750574, tags Assets, ProfitLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures AUBURN NATIONAL BANCORPORATION, INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AUBURN NATIONAL BANCORPORATION, INC (CIK 750574) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-28, and the most recent 10-K annual report was filed 2026-03-17. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 203 8-K or 6-K reports in AUBURN NATIONAL BANCORPORATION, INC’s recent EDGAR index, the 4 listed here run from 2026-05-13 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 750574 is on the EDGAR company page; the latest 10-K there is dated 2026-03-17 and the oldest filing in the recent index dates from 2008-02-08. Insider trades for AUBURN NATIONAL BANCORPORATION, INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aurelion inc. bullish and bearish analyst opinions

For “Aurelion inc. bullish and bearish analyst opinions”, the matching SEC registrant is Aurelion Inc., which trades as AURE and files under Central Index Key 1765850. EDGAR puts it in the “Finance Services” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Prestige Wealth Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-22, across 147 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-01-06 by Aurelion Inc. (CIK 1765850) — source document:

On July 10, 2023, we completed the IPO of 1,000,000 ordinary shares of par value of $0.000625. The ordinary shares were sold at an offering price of $5.00 per share. On February 1, 2024, the Company completed its recapitalization where ordinary shares were re-designated and re-classified as Class A Ordinary Shares and Class B Ordinary Shares and Class A Ordinary Shares began trading on the Nasdaq Capital Market. In July 2024, Prestige Asset Management Limited (“PAM”), a Hong Kong corporation previously wholly owned by us, submitted an application of cessation of business to the SFC, to notify the SFC that it would be ceasing its business of regulated activities under SFO, including regulated activities related to advising on securities (SFO Type 4 License) and regulated activities related to asset management (SFO Type 9 License), from August 8, 2024.

Financial trend for Aurelion Inc. from annual reports, periods 2021-09-30 to 2024-09-30: revenue went from $2.79 million (2021-09-30) to $639,912 (2024-09-30), a change of -77.1%; net income (loss) went from $1.91 million (2021-09-30) to -$6.88 million (2024-09-30), a change of -459.7%; total assets went from $6.00 million (2022-09-30) to $6.33 million (2024-09-30), a change of +5.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1765850, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Aurelion Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Aurelion Inc. (CIK 1765850) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-01-06. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 58 8-K or 6-K reports in Aurelion Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-01 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1765850 is on the EDGAR company page; the latest 20-F there is dated 2026-01-06 and the oldest filing in the recent index dates from 2019-02-15. Insider trades for Aurelion Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Authid inc. bullish and bearish analyst opinions

For “Authid inc. bullish and bearish analyst opinions”, the matching SEC registrant is authID Inc., which trades as AUID and files under Central Index Key 1534154. EDGAR puts it in the “Services-Prepackaged Software” industry code with DE as its state or country of incorporation; its earlier registered name was Ipsidy Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a D filed 2026-10-16, across 578 filings on record. This is reference material, not trading advice.

Financial trend for authID Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $527,415 (2022-12-31) to $2.04 million (2025-12-31), a change of +286.9%; net income (loss) went from -$24.23 million (2022-12-31) to -$17.93 million (2025-12-31), a change of +26.0%; total assets went from $9.37 million (2022-12-31) to $9.98 million (2025-12-31), a change of +6.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1534154, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures authID Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on authID Inc. (CIK 1534154) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 130 8-K or 6-K reports in authID Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-01 to 2026-10-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1534154 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2011-11-09. Insider trades for authID Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Autolus therapeutics plc bullish and bearish analyst opinions

For “Autolus therapeutics plc bullish and bearish analyst opinions”, the matching SEC registrant is Autolus Therapeutics plc, which trades as AUTL and files under Central Index Key 1730463. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with United Kingdom as its state or country of incorporation; its earlier registered name was Autolus Therapeutics Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a EFFECT filed 2026-09-22, across 336 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-27 by Autolus Therapeutics plc (CIK 1730463) — source document:

We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells. We believe our programmed T cell therapies have the potential to be best-in-class and offer patients substantial benefits over the existing standard of care, including the potential for cure in some patients. In November 2024, the United States Food and Drug Administration (the “FDA”) approved our biologics license application (“BLA”) for the marketing of AUCATZYL (obecabtagene autoleucel, also known as obe-cel) in the United States for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (“r/r B-ALL”).

Financial trend for Autolus Therapeutics plc from annual reports, periods 2023-09-30 to 2025-12-31: revenue went from $1.70 million (2023-12-31) to $10.12 million (2024-12-31), a change of +496.0%; net income (loss) went from -$208.38 million (2023-12-31) to -$287.53 million (2025-12-31), a change of -38.0%; total assets went from $406.10 million (2023-09-30) to $589.07 million (2025-12-31), a change of +45.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1730463, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Autolus Therapeutics plc did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Autolus Therapeutics plc (CIK 1730463) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 97 8-K or 6-K reports in Autolus Therapeutics plc’s recent EDGAR index, the 4 listed here run from 2026-06-29 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1730463 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2018-02-09. Insider trades for Autolus Therapeutics plc appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Autozi internet technology (global) ltd. bullish and bearish analyst opinions

For “Autozi internet technology (global) ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Autozi Internet Technology (Global) Ltd., which trades as AZI and files under Central Index Key 1959726. EDGAR puts it in the “Services-Automotive Repair, Services & Parking” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a EFFECT filed 2026-10-16, across 133 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-02-12 by Autozi Internet Technology (Global) Ltd. (CIK 1959726) — source document:

On July 15, 2021, we incorporated Autozi Internet Technology (Global) Ltd. under the laws of the Cayman Islands as our offshore holding company to facilitate offshore financing. On June 2, 2010, we established Autozi Internet Technology Co., Ltd. and commenced our commercial operations. Although we started our business in 2010 as an automotive aftermarket company, we upgraded our business model in 2018 to provide high-quality, affordable and professional one-stop automotive products and services through online and offline channels countrywide. Please also see “Business - Our Supply Chain Cloud and SaaS Platforms - Our Business Model Innovation.” On November 15, 2021, we established Autozi Internet Technology (BVI) Ltd., our wholly owned BVI subsidiary, with no substantial operations in BVI. On June 17, 2022, we established Autozi Internet Technology (HK) Limited, our wholly owned Hong Kong subsidiary, as a holding company with no substantial operations in Hong Kong.

Financial trend for Autozi Internet Technology (Global) Ltd. from annual reports, periods 2022-09-30 to 2025-09-30: revenue went from $120.35 million (2022-09-30) to $122.80 million (2025-09-30), a change of +2.0%; net income (loss) went from -$6.17 million (2022-09-30) to -$16.57 million (2025-09-30), a change of -168.8%; total assets went from $19.04 million (2023-09-30) to $12.00 million (2025-09-30), a change of -37.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1959726, tags Assets, ProfitLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Autozi Internet Technology (Global) Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Autozi Internet Technology (Global) Ltd. (CIK 1959726) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 33 8-K or 6-K reports in Autozi Internet Technology (Global) Ltd.’s recent EDGAR index, the 4 listed here run from 2026-06-23 to 2026-08-31, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1959726 is on the EDGAR company page; the latest 20-F there is dated 2026-02-12 and the oldest filing in the recent index dates from 2023-01-18. Insider trades for Autozi Internet Technology (Global) Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Aytu biopharma, inc. bullish and bearish analyst opinions

For “Aytu biopharma, inc. bullish and bearish analyst opinions”, the matching SEC registrant is AYTU BIOPHARMA, INC, which trades as AYTU and files under Central Index Key 1385818. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was AYTU BIOSCIENCE, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a DEF 14A filed 2026-10-22, across 906 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-09-22 by AYTU BIOPHARMA, INC (CIK 1385818) — source document:

Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. We were originally incorporated as Rosewind Corporation on August 9, 2002, in the state of Colorado and re-incorporated as Aytu BioScience, Inc. in the state of Delaware on June 8, 2015. In March 2021, we changed our name to Aytu BioPharma, Inc. Our common stock trades on the Nasdaq Capital Market LLC (the “Nasdaq”) under the ticker symbol “AYTU.” Our principal office is located at 7900 East Union Avenue, Suite 920, Denver, Colorado 80237, and our telephone number is (720) 437-6580.

Financial trend for AYTU BIOPHARMA, INC from annual reports, periods 2023-06-30 to 2026-06-30: net income (loss) went from -$17.05 million (2023-06-30) to -$14.25 million (2026-06-30), a change of +16.4%; total assets went from $136.46 million (2023-06-30) to $105.01 million (2026-06-30), a change of -23.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1385818, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures AYTU BIOPHARMA, INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on AYTU BIOPHARMA, INC (CIK 1385818) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-22, and the most recent 10-K annual report was filed 2026-09-22. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 224 8-K or 6-K reports in AYTU BIOPHARMA, INC’s recent EDGAR index, the 4 listed here run from 2026-04-02 to 2026-09-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1385818 is on the EDGAR company page; the latest 10-K there is dated 2026-09-22 and the oldest filing in the recent index dates from 2007-01-11. Insider trades for AYTU BIOPHARMA, INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Baosheng media group holdings limited bullish and bearish analyst opinions

For “Baosheng media group holdings limited bullish and bearish analyst opinions”, the matching SEC registrant is Baosheng Media Group Holdings Ltd, which trades as BAOS and files under Central Index Key 1811216. EDGAR puts it in the “Services-Business Services, NEC” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-16, across 135 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-30 by Baosheng Media Group Holdings Ltd (CIK 1811216) — source document:

As a holding company with no operations of our own, our operations are conducted in China through our wholly owned PRC subsidiaries, Beijing Baosheng and its subsidiaries, Baosheng Network and its subsidiary, and Beijing Zhiding. Holders of our Ordinary Shares will not directly hold any equity interests in our operating subsidiaries. This structure involves unique risks to investors. The Chinese regulatory authorities could disallow our corporate structure, which would likely result in a material change in our operations and/or a material change in the value of our securities, including that it could cause the value of such securities to significantly decline or become worthless. ​ We initially conducted our business through Beijing Baosheng, a PRC company formed on October 17, 2014. ​ With the growth of our business, Horgos Baosheng was formed as a limited liability company in the PRC on August 30, 2016, and Kashi Baosheng was formed as a limited liability company in the PRC on May 15, 2018.

Financial trend for Baosheng Media Group Holdings Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.42 million (2022-12-31) to $568,993 (2025-12-31), a change of -76.4%; net income (loss) went from -$23.74 million (2022-12-31) to -$12.02 million (2025-12-31), a change of +49.4%; total assets went from $58.05 million (2022-12-31) to $12.42 million (2025-12-31), a change of -78.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1811216, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Baosheng Media Group Holdings Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Baosheng Media Group Holdings Ltd (CIK 1811216) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 59 8-K or 6-K reports in Baosheng Media Group Holdings Ltd’s recent EDGAR index, the 4 listed here run from 2026-09-02 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1811216 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2020-05-06. Insider trades for Baosheng Media Group Holdings Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Bicara therapeutics inc. common stock bullish and bearish analyst opinions

For “Bicara therapeutics inc. common stock bullish and bearish analyst opinions”, the matching SEC registrant is Bicara Therapeutics Inc., which trades as BCAX and files under Central Index Key 2023658. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 144 filed 2026-10-21, across 263 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-30 by Bicara Therapeutics Inc. (CIK 2023658) — source document:

We are a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. We have built a platform designed to facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This dual-targeting approach both enhances drug exposure within the tumor microenvironment, or TME, and limits systemic toxicity. This approach was deployed in the development of our lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-β, ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-β signaling within the TME. Ficerafusp alfa directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells, which we believe will drive the tumor penetration of immune cells that lead to deep and durable responses and an increase in overall survival, or OS.

Financial trend for Bicara Therapeutics Inc. from annual reports, periods 2023-12-31 to 2025-12-31: net income (loss) went from -$51.98 million (2023-12-31) to -$137.95 million (2025-12-31), a change of -165.4%; total assets went from $233.98 million (2023-12-31) to $430.99 million (2025-12-31), a change of +84.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2023658, tags Assets, NetIncomeLoss; 3 periods shown, dashes mark figures Bicara Therapeutics Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Bicara Therapeutics Inc. (CIK 2023658) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 20 8-K or 6-K reports in Bicara Therapeutics Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-10 to 2026-08-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2023658 is on the EDGAR company page; the latest 10-K there is dated 2026-03-30 and the oldest filing in the recent index dates from 2024-06-10. Insider trades for Bicara Therapeutics Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Biofrontera ag bullish and bearish analyst opinions

For “Biofrontera ag bullish and bearish analyst opinions”, the matching SEC registrant is Biofrontera Inc., which trades as BFRI, BFRIW and files under Central Index Key 1858685. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-14, across 364 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-19 by Biofrontera Inc. (CIK 1858685) — source document:

We are a United States based biopharmaceutical company engaging in the development, manufacturing, and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (“PDT”). The Company’s products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamp series (together, the “RhodoLED Lamps”), are used for the treatment of actinic keratosis (“AK”), a common skin condition characterized by the growth of pre-cancerous lesions (or “AKs”). With our national commercial team, we generate revenue by selling our products directly to dermatology offices and groups. We were formed in 2015 as Biofrontera Inc., a Delaware corporation, and a wholly owned subsidiary of Biofrontera AG, a stock corporation organized under the laws of Germany.

Financial trend for Biofrontera Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $28.67 million (2022-12-31) to $41.70 million (2025-12-31), a change of +45.4%; net income (loss) went from -$640,000 (2022-12-31) to -$10.54 million (2025-12-31), a change of -1546.2%; total assets went from $50.88 million (2022-12-31) to $28.56 million (2025-12-31), a change of -43.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1858685, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Biofrontera Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Biofrontera Inc. (CIK 1858685) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 99 8-K or 6-K reports in Biofrontera Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-14 to 2026-09-14, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1858685 is on the EDGAR company page; the latest 10-K/A there is dated 2026-07-22 and the oldest filing in the recent index dates from 2021-05-07. Insider trades for Biofrontera Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Biolinerx ltd. bullish and bearish analyst opinions

For “Biolinerx ltd. bullish and bearish analyst opinions”, the matching SEC registrant is BioLineRx Ltd., which trades as BLRX and files under Central Index Key 1498403. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Israel as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-23, across 617 filings on record. This is reference material, not trading advice.

Financial trend for BioLineRx Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2022-12-31) to $1.18 million (2025-12-31); net income (loss) went from -$24.95 million (2022-12-31) to -$2.03 million (2025-12-31), a change of +91.9%; total assets went from $76.38 million (2022-12-31) to $40.91 million (2025-12-31), a change of -46.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1498403, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures BioLineRx Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BioLineRx Ltd. (CIK 1498403) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 399 8-K or 6-K reports in BioLineRx Ltd.’s recent EDGAR index, the 4 listed here run from 2026-08-31 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 617 recent EDGAR filings, BioLineRx Ltd. most often filed 6-K (399), 424B5 (31), SC 13G/A (23), SC 13G (19). A selection from 2026-08-31 to 2026-10-02:

The full record for CIK 1498403 is on the EDGAR company page; the latest 20-F there is dated 2026-03-23 and the oldest filing in the recent index dates from 2010-09-24. Insider trades for BioLineRx Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Biote corp. bullish and bearish analyst opinions

For “Biote corp. bullish and bearish analyst opinions”, the matching SEC registrant is biote Corp., which trades as BTMD and files under Central Index Key 1819253. EDGAR puts it in the “Medicinal Chemicals & Botanical Products” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was Haymaker Acquisition Corp. III. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G/A filed 2026-09-18, across 410 filings on record. This is reference material, not trading advice.

Financial trend for biote Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $164.96 million (2022-12-31) to $192.22 million (2025-12-31), a change of +16.5%; net income (loss) went from -$969,000 (2022-12-31) to $27.05 million (2025-12-31), a change of +2891.0%; total assets went from $111.64 million (2022-12-31) to $107.61 million (2025-12-31), a change of -3.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1819253, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures biote Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on biote Corp. (CIK 1819253) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 63 8-K or 6-K reports in biote Corp.’s recent EDGAR index, the 4 listed here run from 2026-05-06 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 410 recent EDGAR filings, biote Corp. most often filed 4 (105), 8-K (63), 424B3 (49), 3 (23). A selection from 2026-08-07 to 2026-09-18:

The full record for CIK 1819253 is on the EDGAR company page; the latest 10-K there is dated 2026-03-13 and the oldest filing in the recent index dates from 2020-08-06. Insider trades for biote Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Birchtech corp. bullish and bearish analyst opinions

For “Birchtech corp. bullish and bearish analyst opinions”, the matching SEC registrant is Birchtech Corp., which trades as BCHT and files under Central Index Key 728385. EDGAR puts it in the “Measuring & Controlling Devices, NEC” industry code with DE as its state or country of incorporation; its earlier registered name was Midwest Energy Emissions Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-10-05, across 807 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by Birchtech Corp. (CIK 728385) — source document:

We are a provider of specialty activated carbon technologies, delivering innovative solutions for air and water purification. We provide patented and proprietary technologies for mercury emissions capture to the coal-fired utility sector, and are developing disruptive water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Products and Services Mercury Emissions We provide mercury capture solutions for coal-fired power plants driven by our patented two-part SEA® process using a powerful combination of science and engineering. Our leading-edge services have been shown to achieve mercury emissions removal at a significantly lower cost and with less operational impact to coal-fired power plants than other used methods, while maintaining and/or increasing power plant output and preserving the marketability of byproducts for beneficial use.

Financial trend for Birchtech Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $21.62 million (2022-12-31) to $17.63 million (2025-12-31), a change of -18.5%; net income (loss) went from -$1.58 million (2022-12-31) to -$3.03 million (2025-12-31), a change of -91.3%; total assets went from $9.34 million (2022-12-31) to $9.24 million (2025-12-31), a change of -1.1%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 728385, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Birchtech Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Birchtech Corp. (CIK 728385) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2025-03-04, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 157 8-K or 6-K reports in Birchtech Corp.’s recent EDGAR index, the 4 listed here run from 2026-03-17 to 2026-07-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 728385 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2001-08-09. Insider trades for Birchtech Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Braemar plc bullish and bearish analyst opinions

Read from its name, “Braemar plc” is a the United Kingdom entity — “plc” is the UK public limited company form, so the company’s accounts are filed at Companies House. Its accounts and exchange notices are published through Companies House and the London Stock Exchange RNS announcements (find-and-update.company-information.service.gov.uk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Braemar plc bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Braemar plc” appears in 2492+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “braemar” (search terms considered: braemar).

The wording suggests a business based in the United Kingdom. Companies there file with the London Stock Exchange and the FCA National Storage Mechanism rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “braemar” is therefore the the United Kingdom regulator or exchange site, where annual reports and stock-exchange announcements are published.

In the 100 most relevant full-text hits returned for “Braemar plc”, filings range from 2022-11-28 to 2026-09-24. The filers whose documents mention it most often are KINETICS PORTFOLIOS TRUST (CIK 0001113229) (28 hits); DFA INVESTMENT TRUST CO (CIK 0000896162) (16 hits); EQ ADVISORS TRUST (CIK 0001027263) (16 hits); Icon Energy Corp (ICON) (CIK 0001995574) (12 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 19 entities whose registered name contains the word “braemar”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “braemar” 19. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “braemar” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Brightspire capital, inc. bullish and bearish analyst opinions

For “Brightspire capital, inc. bullish and bearish analyst opinions”, the matching SEC registrant is BrightSpire Capital, Inc., which trades as BRSP and files under Central Index Key 1717547. EDGAR puts it in the “Real Estate Investment Trusts” industry code with MD as its state or country of incorporation; its earlier registered name was Colony Credit Real Estate, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21, across 369 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-18 by BrightSpire Capital, Inc. (CIK 1717547) — source document:

References to “we,” “us,” “our,” or the “Company” refer to BrightSpire Capital, Inc., a Maryland corporation, together with its consolidated subsidiaries, unless the context specifically requires otherwise. References to the “OP” refer to BrightSpire Capital Operating Company, LLC a Delaware limited liability company, the operating company of the Company. We are an internally-managed commercial real estate (“CRE”) credit real estate investment trust (“REIT”) focused on originating, acquiring, financing and managing a diversified portfolio consisting primarily of CRE debt investments and net leased properties. CRE debt investments primarily consist of senior mortgage loans, which is our primary investment strategy. Additionally, we may also selectively originate mezzanine loans and preferred equity investments, which may include profit participations.

Financial trend for BrightSpire Capital, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $364.62 million (2022-12-31) to $330.59 million (2025-12-31), a change of -9.3%; net income (loss) went from $45.79 million (2022-12-31) to -$31.15 million (2025-12-31), a change of -168.0%; total assets went from $4.75 billion (2022-12-31) to $3.56 billion (2025-12-31), a change of -25.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1717547, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures BrightSpire Capital, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on BrightSpire Capital, Inc. (CIK 1717547) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-07-28, and the most recent 10-K annual report was filed 2026-02-18. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 94 8-K or 6-K reports in BrightSpire Capital, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-16 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1717547 is on the EDGAR company page; the latest 10-K there is dated 2026-02-18 and the oldest filing in the recent index dates from 2017-09-29. Insider trades for BrightSpire Capital, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Brightstar lottery plc bullish and bearish analyst opinions

For “Brightstar lottery plc bullish and bearish analyst opinions”, the matching SEC registrant is Brightstar Lottery PLC, which trades as BRSL and files under Central Index Key 1619762. EDGAR puts it in the “Services-Miscellaneous Amusement & Recreation” industry code with United Kingdom as its state or country of incorporation; its earlier registered name was International Game Technology PLC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-22, across 397 filings on record. This is reference material, not trading advice.

Financial trend for Brightstar Lottery PLC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.60 billion (2022-12-31) to $2.51 billion (2025-12-31), a change of -3.3%; net income (loss) went from $275.00 million (2022-12-31) to $147.00 million (2025-12-31), a change of -46.5%; total assets went from $10.43 billion (2022-12-31) to $9.16 billion (2025-12-31), a change of -12.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1619762, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Brightstar Lottery PLC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Brightstar Lottery PLC (CIK 1619762) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-02-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 234 8-K or 6-K reports in Brightstar Lottery PLC’s recent EDGAR index, the 4 listed here run from 2026-09-10 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 397 recent EDGAR filings, Brightstar Lottery PLC most often filed 6-K (234), 4 (21), 3 (17), 425 (17). A selection from 2026-07-16 to 2026-08-14:

The full record for CIK 1619762 is on the EDGAR company page; the latest 20-F there is dated 2026-02-24 and the oldest filing in the recent index dates from 2014-10-01. Insider trades for Brightstar Lottery PLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cadrenal therapeutics, inc. common stock bullish and bearish analyst opinions

For “Cadrenal therapeutics, inc. common stock bullish and bearish analyst opinions”, the matching SEC registrant is Cadrenal Therapeutics, Inc., which trades as CVKD and files under Central Index Key 1937993. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 277 filings on record. This is reference material, not trading advice.

Our broader pipeline includes two additional clinical-stage assets—tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (“VKA”) (a warfarin replacement for patients with complex needs) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Specifically, our focus for tecarfarin is for chronic use in patients with kidney dysfunction or left ventricular assist devices (“LVADs”). Tecarfarin has been specifically designed to overcome metabolic factors that can make warfarin less reliable. Frunexian is a first-in-class, Phase 2-ready intravenous (“IV”) Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces is significant. Frunexian is the only IV FXIa inhibitor in clinical development that targets the acute/critical care hospital setting exclusively.

Analyst ratings, price targets and “bullish” or “bearish” calls on Cadrenal Therapeutics, Inc. (CIK 1937993) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Updated Oct 25, 2026 ET

Calcimedica, inc. bullish and bearish analyst opinions

For “Calcimedica, inc. bullish and bearish analyst opinions”, the matching SEC registrant is CalciMedica, Inc., which trades as CALC and files under Central Index Key 1534133. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was CalciMedica, Inc. /DE/. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-16, across 530 filings on record. This is reference material, not trading advice.

Financial trend for CalciMedica, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$7.82 million (2022-12-31) to -$29.56 million (2025-12-31), a change of -277.8%; total assets went from $3.35 million (2022-12-31) to $13.59 million (2025-12-31), a change of +305.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1534133, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures CalciMedica, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CalciMedica, Inc. (CIK 1534133) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-03. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 72 8-K or 6-K reports in CalciMedica, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-02 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 530 recent EDGAR filings, CalciMedica, Inc. most often filed 4 (231), 8-K (72), 3 (29), 10-Q (18). A selection from 2026-10-05 to 2026-10-05:

The full record for CIK 1534133 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2011-11-08. Insider trades for CalciMedica, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Calidi biotherapeutics, inc. bullish and bearish analyst opinions

For “Calidi biotherapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Calidi Biotherapeutics, Inc., which trades as CLDI, CLDWW and files under Central Index Key 1855485. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation; its earlier registered name was Calidi Biotherapeutics, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-09-25, across 406 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-27 by Calidi Biotherapeutics, Inc. (CIK 1855485) — source document:

We are a publicly traded biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. Our proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. We expect to file an investigational new drug (“ IND”) application for a Phase I trial by the end of 2026 with CLD-401, the first compound from the RedTail platform, delivering IL-15 superagonist to the tumor microenvironment (“TME”).

Financial trend for Calidi Biotherapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue was tagged only for 2022-12-31 at $45,000; net income (loss) went from -$25.43 million (2022-12-31) to -$19.91 million (2025-12-31), a change of +21.7%; total assets went from $2.60 million (2022-12-31) to $8.86 million (2025-12-31), a change of +241.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1855485, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Calidi Biotherapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Calidi Biotherapeutics, Inc. (CIK 1855485) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 104 8-K or 6-K reports in Calidi Biotherapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-31 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1855485 is on the EDGAR company page; the latest 10-K there is dated 2026-03-27 and the oldest filing in the recent index dates from 2021-05-17. Insider trades for Calidi Biotherapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Capstone energy+, inc. bullish and bearish analyst opinions

For “Capstone energy+, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Capstone Holding Corp., which trades as CAPS and files under Central Index Key 887151. EDGAR puts it in the “Wholesale-Lumber & Other Construction Materials” industry code with NV as its state or country of incorporation; its earlier registered name was Capstone Therapeutics Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21, across 847 filings on record. This is reference material, not trading advice.

Financial trend for Capstone Holding Corp. from annual reports, periods 2018-12-31 to 2025-12-31: revenue went from -$2.00 million (2018-12-31) to $44.88 million (2024-12-31), a change of +2343.8%; net income (loss) went from $380,000 (2018-12-31) to -$21.23 million (2025-12-31), a change of -5686.8%; total assets went from $1.48 million (2018-12-31) to $51.38 million (2025-12-31), a change of +3378.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 887151, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Capstone Holding Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Capstone Holding Corp. (CIK 887151) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-01, and the most recent 10-K annual report was filed 2026-04-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 180 8-K or 6-K reports in Capstone Holding Corp.’s recent EDGAR index, the 4 listed here run from 2026-09-29 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 887151 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-17 and the oldest filing in the recent index dates from 1994-02-11. Insider trades for Capstone Holding Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cathay consolidated, inc. bullish and bearish analyst opinions

What this search refers to. “Cathay Consolidated, Inc.” does not match an EDGAR registrant; Cathay-named companies span Taiwan, Hong Kong and the U.S., so the registry depends on where it is incorporated. Corporate-registry check: OpenCorporates search for “Cathay consolidated, inc.”.

No SEC filer could be matched to “Cathay consolidated, inc. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Cathay consolidated, inc.” appears in 1062+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “cathay” (search terms considered: cathay, consolidated).

A broader EDGAR full-text search for the shorter phrase “Cathay consolidated inc.” finds 1062+ filing documents; among the top 100, the filers mentioning it most are WisdomTree Trust (CIK 0001350487) (63); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (14); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (9). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 100 most relevant full-text hits returned for “Cathay consolidated, inc.”, filings range from 2024-09-26 to 2026-09-24. The filers whose documents mention it most often are WisdomTree Trust (CIK 0001350487) (63 hits); DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (14 hits); DIMENSIONAL EMERGING MARKETS VALUE FUND (CIK 0000896163) (9 hits); DFA INVESTMENT TRUST CO (CIK 0000896162) (9 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

Word by word, the number of EDGAR registrant names containing each term of this search is: “cathay” 25, “consolidated” 267. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “cathay” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Cementos pacasmayo s.a.a. bullish and bearish analyst opinions

The legal-form ending in “Cementos pacasmayo s.a.a.” is the clue: “S.A.A.” is the Peruvian open stock corporation form used by listed companies. A company of that kind reports in Peru, so the place to read its annual report and announcements is the Lima Stock Exchange (BVL) and SMV disclosures — www.smv.gob.pe.

No SEC filer could be matched to “Cementos pacasmayo s.a.a. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Cementos pacasmayo s.a.a.” appears in 1073+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “cementos” (search terms considered: cementos, pacasmayo).

In the 100 most relevant full-text hits returned for “Cementos pacasmayo s.a.a.”, filings range from 2003-03-04 to 2026-10-15. The filers whose documents mention it most often are CEMENTOS PACASMAYO SAA (CPAC) (CIK 0001221029) (99 hits); JPMorgan Chase Bank, N.A. - ADR Depositary (CIK 0001474274) (3 hits); ZEMEX CORP (CIK 0000075644) (1 hit); Farragut Holdings, Inc. (CIK 0002130390) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 5 entities whose registered name contains the word “cementos”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “cementos” 5, “pacasmayo” 2. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “cementos” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Cerenome, inc. bullish and bearish analyst opinions

For “Cerenome, inc. bullish and bearish analyst opinions”, the matching SEC registrant is CERENOME, INC., which trades as CNSY and files under Central Index Key 1095981. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation; its earlier registered name was PLUS THERAPEUTICS, INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-02, across 1000 filings on record. This is reference material, not trading advice.

Financial trend for CERENOME, INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $4.91 million (2023-12-31) to $5.21 million (2025-12-31), a change of +6.1%; net income (loss) went from -$20.27 million (2022-12-31) to -$22.39 million (2025-12-31), a change of -10.4%; total assets went from $23.87 million (2022-12-31) to $16.32 million (2025-12-31), a change of -31.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1095981, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures CERENOME, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CERENOME, INC. (CIK 1095981) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 271 8-K or 6-K reports in CERENOME, INC.’s recent EDGAR index, the 4 listed here run from 2026-08-04 to 2026-10-02, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1095981 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2011-02-14. Insider trades for CERENOME, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Chenghe acquisition iii co. units bullish and bearish analyst opinions

For “Chenghe acquisition iii co. units bullish and bearish analyst opinions”, the matching SEC registrant is Chenghe Acquisition III Co., which trades as CHEC, CHECU, CHECW and files under Central Index Key 2047177. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-05, across 43 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-25 by Chenghe Acquisition III Co. (CIK 2047177) — source document:

We are a blank check company incorporated as a Cayman Islands exempted company whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this Annual Report as our initial business combination. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. We may pursue an initial business combination target in any industry or geographic region. Our co-sponsors are affiliated with Chenghe Group Ltd. (“Chenghe Group”), an investment holding company with an advisory practice, and a repeat SPAC sponsor which has backed and led multiple SPAC vehicles from the formation of such vehicles to consummation of their initial business combinations.

Financial trend for Chenghe Acquisition III Co. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) was tagged only for 2025-12-31 at $1.09 million; total assets went from $177,137 (2024-12-31) to $128.68 million (2025-12-31), a change of +72543.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2047177, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Chenghe Acquisition III Co. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Chenghe Acquisition III Co. (CIK 2047177) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Chenghe Acquisition III Co. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 6 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2025-09-17.

Current reports. Of the 4 8-K or 6-K reports in Chenghe Acquisition III Co.’s recent EDGAR index, the 4 listed here run from 2025-09-18 to 2026-05-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2047177 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2025-01-31. Insider trades for Chenghe Acquisition III Co. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Chi sheng pharma & biotech co., ltd bullish and bearish analyst opinions

The legal-form ending in “Chi sheng pharma & biotech co., ltd” is the clue: “Co., Ltd.” is the English rendering used by limited companies across East Asia. A company of that kind reports in China, Taiwan, Korea or Japan, so the place to read its annual report and announcements is the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) — mops.twse.com.tw.

No SEC filer could be matched to “Chi sheng pharma & biotech co., ltd bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Chi sheng pharma & biotech co.,”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “chi” (search terms considered: chi, sheng, pharma, biotech).

Even the shorter phrase “Chi sheng pharma” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (chi, sheng, pharma, biotech) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 199+ entities whose registered name contains the word “chi”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “chi” 204, “sheng” 65, “pharma” 470, “biotech” 384. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “chi”: A-CHI-28-FUND, A SERIES OF AX-ABVC-FUNDS, LLC (CIK 1685662), A-CHI-28-PR-FUND, A SERIES OF AX-ABVC-FUNDS, LLC (CIK 1716594), ABRUZZO ELSA CHI (CIK 1336062); containing “sheng”: CHANG SHENG-CHUN (CIK 1682964), CHANG SHENG-YIH (CIK 1841429), CHANG TZONZ-SHENG (CIK 2113710); containing “pharma”: 024 PHARMA, INC. (CIK 1307969), 1200 PHARMA LLC (CIK 1723507), 22C TARGET PHARMA INVESTORS ROLLOVER, LLC (CIK 1746768); containing “biotech”: 2009 BIOTECH VSC, L.P. (CIK 1463664), 2009 BIOTECH VSP, L.P. (CIK 1463663), 2010 BIOTECH VSC, L.P. (CIK 1486163). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “chi” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Chimeric therapeutics limited bullish and bearish analyst opinions

Read from its name, “Chimeric therapeutics limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Chimeric therapeutics limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Chimeric therapeutics limited” appears in 36 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “chimeric” (search terms considered: chimeric, therapeutics).

In the 36 most relevant full-text hits returned for “Chimeric therapeutics limited”, filings range from 2020-11-17 to 2026-01-26. The filers whose documents mention it most often are Scopus BioPharma Inc. (SCPS) (CIK 0001772028) (10 hits); Radiopharm Theranostics Ltd (CIK 0001949257) (8 hits); ENANTA PHARMACEUTICALS INC (ENTA) (CIK 0001177648) (7 hits); Radiopharm Theranostics Ltd (RADX) (CIK 0001949257) (5 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 0 entities whose registered name contains the word “chimeric”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “chimeric” 0, “therapeutics” 464. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “therapeutics”: 3D BIO THERAPEUTICS, A SERIES OF VUVP FUND I, LLC (CIK 1921810), 3D THERAPEUTICS, LLC (CIK 1593782), 3F THERAPEUTICS INC (CIK 1073650). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “chimeric” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Cirrus aircraft limited bullish and bearish analyst opinions

“Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. The name “Cirrus aircraft limited” therefore points to a company organised in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), and its official disclosures are on that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk), not on EDGAR.

No SEC filer could be matched to “Cirrus aircraft limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Cirrus aircraft limited” appears in 2 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “cirrus” (search terms considered: cirrus, aircraft).

In the 2 most relevant full-text hits returned for “Cirrus aircraft limited”, filings range from 2026-08-26 to 2026-09-02. The filers whose documents mention it most often are JNL SERIES TRUST (CIK 0000933691) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 27 entities whose registered name contains the word “cirrus”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “cirrus” 27, “aircraft” 136. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “cirrus” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Colombier acquisition corp. iii forecast and analysis

For “Colombier acquisition corp. iii forecast and analysis”, the matching SEC registrant is Colombier Acquisition Corp. III, which trades as CLBR, CLBR-UN, CLBR-WT and files under Central Index Key 2091024. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-13, across 25 filings on record. This is reference material, not trading advice.

Financial trend for Colombier Acquisition Corp. III from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $366,020 (2026-03-31) to $2.42 million (2026-06-30), a change of +560.3%; total assets went from $301.23 million (2026-03-31) to $303.72 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2091024, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Colombier Acquisition Corp. III did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Colombier Acquisition Corp. III (CIK 2091024) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Colombier Acquisition Corp. III — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B4, S-1, S-1/A) appear in its recent index, the newest dated 2026-02-04.

Current reports. Of the 3 8-K or 6-K reports in Colombier Acquisition Corp. III’s recent EDGAR index, the 3 listed here run from 2026-02-05 to 2026-03-25, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 25 recent EDGAR filings, Colombier Acquisition Corp. III most often filed 3 (11), 8-K (3), 10-Q (2), SCHEDULE 13G (1). A selection from 2026-02-05 to 2026-08-13:

The full record for CIK 2091024 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-10-17. Insider trades for Colombier Acquisition Corp. III appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Controladora vuela compañía de aviación, s.a.b. de c.v. bullish and bearish analyst opinions

For “Controladora vuela compañía de aviación, s.a.b. de c.v. bullish and bearish analyst opinions”, the matching SEC registrant is Controladora Vuela Compania de Aviacion, S.A.B. de C.V., which trades as VLRS, CTTRF and files under Central Index Key 1520504. EDGAR puts it in the “Air Transportation, Scheduled” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-06, across 443 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-28 by Controladora Vuela Compania de Aviacion, S.A.B. de C.V. (CIK 1520504) — source document:

We were founded on October 27, 2005 under the name Controladora Vuela Compañía de Aviación, S.A. de C.V. by Blue Sky Investments, S.à r.l., Discovery Air Investments, L.P., Corporativo Vasco de Quiroga, S.A. de C.V. and Sinca Inbursa, S.A. de C.V., Sociedad de Inversión de Capitales. On July 16, 2010, we became a variable capital investment promotion stock corporation ( sociedad anónima promotora de inversión de capital variable ). On September 23, 2013, we and certain of our shareholders completed a dual-listing initial public offering on the NYSE and the Mexican Stock Exchange. We raised approximately U.S. $207.7 million of gross proceeds from the global offering of 173,076,910 Series A shares, consisting of (i) an offering of Series A shares in Mexico and (ii) a concurrent international offering of CPOs in the form of ADSs in the United States and other countries outside of Mexico, at a public offering price of U.S. $1.20 dollars per share or U.S. $12.00 per ADS. Each ADS represents ten CPOs and each CPO represents a financial interest in one of our Series A shares.

Financial trend for Controladora Vuela Compania de Aviacion, S.A.B. de C.V. from annual reports, periods 2018-12-31 to 2021-12-31: net income (loss) went from -942,882,000 MXN (2018-12-31) to 2,120,551,000 MXN (2021-12-31), a change of +324.9%; total assets went from 56,724,683,000 MXN (2018-12-31) to 82,016,361,000 MXN (2021-12-31), a change of +44.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1520504, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures Controladora Vuela Compania de Aviacion, S.A.B. de C.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Controladora Vuela Compania de Aviacion, S.A.B. de C.V. (CIK 1520504) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 317 8-K or 6-K reports in Controladora Vuela Compania de Aviacion, S.A.B. de C.V.’s recent EDGAR index, the 4 listed here run from 2026-08-18 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1520504 is on the EDGAR company page; the latest 20-F there is dated 2026-04-28 and the oldest filing in the recent index dates from 2013-04-05. Insider trades for Controladora Vuela Compania de Aviacion, S.A.B. de C.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Corvel corporation bullish and bearish analyst opinions

For “Corvel corporation bullish and bearish analyst opinions”, the matching SEC registrant is CORVEL CORP, which trades as CRVL and files under Central Index Key 874866. EDGAR puts it in the “Insurance Agents, Brokers & Service” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-01, across 1000 filings on record. This is reference material, not trading advice.

Financial trend for CORVEL CORP from annual reports, periods 2023-03-31 to 2026-03-31: revenue went from $718.56 million (2023-03-31) to $958.53 million (2026-03-31), a change of +33.4%; net income (loss) went from $66.36 million (2023-03-31) to $110.34 million (2026-03-31), a change of +66.3%; total assets went from $393.92 million (2023-03-31) to $642.99 million (2026-03-31), a change of +63.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 874866, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures CORVEL CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on CORVEL CORP (CIK 874866) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-05-22. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 54 8-K or 6-K reports in CORVEL CORP’s recent EDGAR index, the 4 listed here run from 2026-05-20 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1000 recent EDGAR filings, CORVEL CORP most often filed 4 (724), 144 (84), 8-K (54), SC 13G/A (32). A selection from 2026-09-15 to 2026-10-01:

The full record for CIK 874866 is on the EDGAR company page; the latest 10-K there is dated 2026-05-22 and the oldest filing in the recent index dates from 2018-08-29. Insider trades for CORVEL CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Curbline properties corp. bullish and bearish analyst opinions

For “Curbline properties corp. bullish and bearish analyst opinions”, the matching SEC registrant is Curbline Properties Corp., which trades as CURB and files under Central Index Key 2027317. EDGAR puts it in the “Real Estate” industry code with MD as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-23, across 142 filings on record. This is reference material, not trading advice.

Financial trend for Curbline Properties Corp. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $73.14 million (2022-12-31) to $182.89 million (2025-12-31), a change of +150.1%; net income (loss) went from $25.73 million (2022-12-31) to $39.88 million (2025-12-31), a change of +55.0%; total assets went from $921.63 million (2023-12-31) to $2.47 billion (2025-12-31), a change of +168.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2027317, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Curbline Properties Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Curbline Properties Corp. (CIK 2027317) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-10-22, and the most recent 10-K annual report was filed 2026-02-10. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 23 8-K or 6-K reports in Curbline Properties Corp.’s recent EDGAR index, the 4 listed here run from 2026-07-01 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 142 recent EDGAR filings, Curbline Properties Corp. most often filed 4 (54), 8-K (23), 3 (12), SCHEDULE 13G/A (10). A selection from 2026-09-15 to 2026-10-23:

The full record for CIK 2027317 is on the EDGAR company page; the latest 10-K there is dated 2026-02-10 and the oldest filing in the recent index dates from 2024-06-28. Insider trades for Curbline Properties Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Cushman & wakefield plc bullish and bearish analyst opinions

For “Cushman & wakefield plc bullish and bearish analyst opinions”, the matching SEC registrant is Cushman & Wakefield Ltd., which trades as CWK and files under Central Index Key 1628369. EDGAR puts it in the “Real Estate” industry code with Bermuda as its state or country of incorporation; its earlier registered name was Cushman & Wakefield plc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-21, across 676 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-19 by Cushman & Wakefield Ltd. (CIK 1628369) — source document:

Led by an experienced executive team, our approximately 53,000 employees in over 350 offices and nearly 60 countries provide exceptional problem-solving, advisory and execution across the built environment, and manage approximately 6.5 billion square feet of commercial real estate globally. Our business is focused on meeting the increasing demands of our clients through comprehensive global offerings including (i) Services, (ii) Leasing, (iii) Capital markets and (iv) Valuation and other services. In 2025, 2024 and 2023, we generated revenues of $10.3 billion, $9.4 billion and $9.5 billion, respectively. Since 2014, we have built a company with the scale and global footprint to effectively serve our multinational and local clients’ needs. Today, Cushman & Wakefield is one of the top three real estate services providers as measured by revenue and workforce.

Financial trend for Cushman & Wakefield Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $10.11 billion (2022-12-31) to $10.29 billion (2025-12-31), a change of +1.8%; net income (loss) went from $196.40 million (2022-12-31) to $88.20 million (2025-12-31), a change of -55.1%; total assets went from $7.95 billion (2022-12-31) to $7.68 billion (2025-12-31), a change of -3.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1628369, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Cushman & Wakefield Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Cushman & Wakefield Ltd. (CIK 1628369) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 112 8-K or 6-K reports in Cushman & Wakefield Ltd.’s recent EDGAR index, the 4 listed here run from 2026-06-15 to 2026-10-21, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1628369 is on the EDGAR company page; the latest 10-K there is dated 2026-02-19 and the oldest filing in the recent index dates from 2014-12-31. Insider trades for Cushman & Wakefield Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Daxor corporation bullish and bearish analyst opinions

For “Daxor corporation bullish and bearish analyst opinions”, the matching SEC registrant is DAXOR CORP, which trades as DXR and files under Central Index Key 27367. EDGAR puts it in the “no SIC description” industry code with NY as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 40-8F-2/A filed 2026-10-09, across 736 filings on record. This is reference material, not trading advice.

Financial trend for DAXOR CORP from annual reports, periods 2010-12-31 to 2011-12-31: revenue went from $1.58 million (2010-12-31) to $1.45 million (2011-12-31), a change of -8.4%; net income (loss) went from $4.97 million (2010-12-31) to -$7.19 million (2011-12-31), a change of -244.6%; total assets went from $91.20 million (2010-12-31) to $85.72 million (2011-12-31), a change of -6.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 27367, tags Assets, NetIncomeLoss, Revenues; 2 periods shown, dashes mark figures DAXOR CORP did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on DAXOR CORP (CIK 27367) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2012-03-28. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 37 8-K or 6-K reports in DAXOR CORP’s recent EDGAR index, the 4 listed here run from 2025-08-07 to 2026-06-24, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 736 recent EDGAR filings, DAXOR CORP most often filed 4 (267), 10-Q (51), 40-17F2 (38), 8-K (37). A selection from 2026-08-31 to 2026-10-09:

The full record for CIK 27367 is on the EDGAR company page; the latest N-CSR there is dated 2026-08-31 and the oldest filing in the recent index dates from 1995-04-18. Insider trades for DAXOR CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET